Shares of InMode Ltd. (NASDAQ:INMD) have been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $28.00 for the company and are predicting that the company will post $0.29 EPS for the current quarter, according to Zacks. Zacks has also given InMode an industry rank of 101 out of 255 based on the ratings given to its competitors.
A number of equities analysts recently commented on the stock. UBS Group assumed coverage on shares of InMode in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $28.00 price objective for the company. Robert W. Baird assumed coverage on shares of InMode in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $27.00 price objective for the company. Barclays assumed coverage on shares of InMode in a research note on Tuesday, September 3rd. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, Canaccord Genuity assumed coverage on shares of InMode in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 price objective for the company.
InMode stock traded down $0.23 during midday trading on Monday, reaching $31.27. The stock had a trading volume of 787,700 shares, compared to its average volume of 947,943. The firm has a fifty day moving average of $26.10. InMode has a twelve month low of $13.06 and a twelve month high of $32.50.
InMode (NASDAQ:INMD) last posted its quarterly earnings data on Tuesday, August 13th. The healthcare company reported $0.45 EPS for the quarter. The firm had revenue of $38.80 million during the quarter. Equities analysts expect that InMode will post 1.38 earnings per share for the current year.
An institutional investor recently bought a new position in InMode stock. Optimum Investment Advisors acquired a new position in InMode Ltd. (NASDAQ:INMD) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,300 shares of the healthcare company’s stock, valued at approximately $28,000. 0.54% of the stock is owned by institutional investors and hedge funds.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
Further Reading: What is a Futures Contract?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.